Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice
- 31 December 1994
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (2) , 183-187
- https://doi.org/10.1016/0959-8049(94)90084-1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278Cancer Chemotherapy and Pharmacology, 1992
- Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamateBiochemical Pharmacology, 1992
- The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatinBiochemical Pharmacology, 1991
- Clinical trials of WR-2721 and cis-platinumInternational Journal of Radiation Oncology*Biology*Physics, 1989
- CarboplatinDrugs, 1989
- Pharmacokinetics of WR-2721Pharmacology & Therapeutics, 1988
- Can WR-2721 be improved upon?Pharmacology & Therapeutics, 1988
- Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouseBritish Journal of Cancer, 1983
- Effects of cisplatin on different haemopoietic progenitor cells in miceBritish Journal of Cancer, 1982
- Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamideBritish Journal of Cancer, 1980